Research Study

Upfront Riociguat and Ambrisentan Combination Therapy for Pulmonary Arterial Hypertension: A Safety and Efficacy Pilot Study
Principal Investigator 
John Swiston

Overview

Body Locations and Systems 
Pulmonary Hypertension
ClinicalTrials.gov# 
NCT03809156
Status 
Recruiting
Study Start/End 
Mar 8, 2019 to Dec 31, 2019
Locations 
Diamond Health Care Centre
Name/Title 
Mami Okada, Research Coordinator
Phone 
604-875-4111 ext.69831
Email Address 
mami.okada@vch.ca
Purpose of Study 

The purpose of this study is to evaluate the safety and efficacy of first-line combination therapy using riociguat with ambrisentan in patients with Pulmonary Arterial Hypertension (PAH).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.